Integrase Interactor 1 (INI1) Deficiency in a Lung Cancer Patient Presents Nonresponse to Immunotherapy and Tazemetostat: A Case Report.
immunotherapy
ini1
lung cancer
smarcb1
tazemetostat
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
accepted:
04
08
2023
medline:
5
9
2023
pubmed:
5
9
2023
entrez:
5
9
2023
Statut:
epublish
Résumé
Integrase interactor 1 (INI1)-deficient lung cancer is extremely rare, often with poor prognosis, and lacks effective treatment. Previous studies have reported the efficacy of immunotherapy and enhancer of the zeste homolog 2 (EZH2) inhibitor tazemetostat in various types of INI1-deficient tumors, such as sarcomas. However, the effectiveness of these treatments in INI1-deficient lung cancer has not yet been verified. We hereby report a case of a patient who was diagnosed with advanced squamous lung cancer with INI1 deficiency and received chemotherapy, immunotherapy, and tazemetostat treatments successively. The patient showed optimal response in the initial chemotherapy combined with anti-programmed cell death protein 1 (PD-1) immunotherapy, made rapid progress in the subsequent stage of maintenance immunotherapy, and showed nonresponse to tazemetostat. To the best of our knowledge, this is the first case of a lung cancer patient with INI1 deficiency who received tazemetostat treatment.
Identifiants
pubmed: 37667707
doi: 10.7759/cureus.42934
pmc: PMC10475322
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e42934Informations de copyright
Copyright © 2023, Chen et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cancer Sci. 2017 Apr;108(4):547-552
pubmed: 28109176
Lancet Oncol. 2022 Jun;23(6):758-767
pubmed: 35588752
Eur J Cancer. 2022 Sep;172:329-331
pubmed: 35820243
Cancer Discov. 2018 Jan;8(1):OF5
pubmed: 29141919
Biochem Soc Trans. 2022 Jun 30;50(3):1143-1150
pubmed: 35587173
Pathology. 2022 Oct;54(6):817-820
pubmed: 35177248
Biomedicines. 2022 Mar 11;10(3):
pubmed: 35327458
Science. 2018 Feb 16;359(6377):770-775
pubmed: 29301958
Cancers (Basel). 2022 Jul 27;14(15):
pubmed: 35892904
Mod Pathol. 2022 Dec;35(12):1860-1869
pubmed: 35864317
Drugs. 2020 Apr;80(5):513-521
pubmed: 32166598
J Thorac Oncol. 2021 Jul;16(7):1176-1187
pubmed: 33845210
Neuro Oncol. 2020 Jun 9;22(6):785-796
pubmed: 31912158
Cancer Cell. 2019 Dec 9;36(6):597-612.e8
pubmed: 31708437
JCI Insight. 2021 Sep 22;6(18):
pubmed: 34375311
J Thorac Oncol. 2022 Mar;17(3):362-387
pubmed: 34808341